For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Teijin: Drug Sales, Profits to Plummet in FY2002
April 22, 2002
- WORLD NEWS IN BRIEF
April 22, 2002
- Hisamitsu: FY2001 Sales Up 6.6% to \69.5 Bil.
April 22, 2002
- Bayer Group to Increase Sales in Japan to \300 Bil. by 2004: Dr Portoff
April 22, 2002
- Pharmacia Starts Joint Research with Keio Univ.
April 22, 2002
- Pharmaceutical Industry Vision Drafted by Korosho
April 22, 2002
- Takeda Puts Brakes on High Hopes for TAK-165 Anticancer Agent
April 22, 2002
- 37 New Drugs Officially Approved
April 22, 2002
- Report on Future Trends in Regenerative Medicine Completed
April 22, 2002
- Korosho Presents Bill for Rivision of PAL to Diet
April 22, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 22, 2002
- 1,576 Firms Apply for Disclosure of PFSB Information
April 22, 2002
- Toshiba Forms Alliance with US Heartlab to Market Cardiovascular Information System
April 22, 2002
- Outline of Relief System for Victims of Tissue Engineering Products Recommended
April 15, 2002
- Terumo Latin America Established in Miami
April 15, 2002
- Plan of Reducing Subsidies to Public Corporations Approved
April 15, 2002
- Nabelin Fuji Science Ties Up with 2 Medical Devices Wholesalers
April 15, 2002
- REGULATORY NEWS IN BRIEF
April 15, 2002
- Oticon: New Hearing Aid Adapto
April 15, 2002
- BULLETIN
April 15, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…